National Conference cum Workshop on Bioinformatics and Computational Biology |
Foundation of Computer Science USA |
NCWBCB - Number 3 |
May 2014 |
Authors: Anita Margret. A, Nargis Begum. T, Prakash. P, Jesubalan. S |
aa631097-ee44-44a8-b225-cfac10bab01c |
Anita Margret. A, Nargis Begum. T, Prakash. P, Jesubalan. S . An In-Silico Approach to Confront Monoamine Oxidase by Synthetic and Herbal Antidepressant Drug. National Conference cum Workshop on Bioinformatics and Computational Biology. NCWBCB, 3 (May 2014), 1-4.
Monoamine oxidase (MAO) is an enzyme that metabolizes monoamines, and are also vital to the inactivation of monoaminergic neurotransmitters, such as serotonin, norepinephrine, dopamine for which they display different specificities. Lower level of such neurotransmitters leads to depression which is considered to be a menace in current scenario and there is need for a treatment. Hence it is necessary to confront Monoamine oxidase (MAO). Antidepressant drugs are formulated to handle a sensitive issue called depression where Venlafaxin a synthetic drug is a highly configured drug for depression . This is referred with Lithium carbonate a chemical which generally has the capacity to tackle depression. The study alternatively compares the compounds essential as anti depressant in Clitoria ternatea which is said to be a brain tonic and Hypericum perforatum whose capsules are standardized as antidepressant drugs. The phytocompounds along with Venlafaxine and lithium carbonate is contested to evaluate their efficiency to combat the protein Monoamine oxidase thereby conflicting depression.